Anavex Life Sciences Corp (AVXL)

[falconer66a]

The abstract Conclusion says it all --- but in a rather timid manner (required for publication; accepted scientific understandings must be delicately and incrementally assailed).

Here's the truth of the study, with a precisely accurate version of the Conclusion (where I've deleted the timid words and inserted the precise ones, in caps):

The safety of ANAVEX2-73 was assessed and MTD was determined. Despite not optimal dosing, both cognitive and functional performance is sustained over at least 12 months, INDICATING that the effect of the compound does not worsen AD symptoms with repeated dosing. In a progressive degenerative disease this is a PREVIOUSLY UN-DEMONSTRATED, positive outcome. The data support further clinical development of ANAVEX2-73 and preparation for a larger confirmatory study is underway.

As with the data and plots presented at the CTAD event, the Anavex2-73 human clinical data are revolutionary. Nothing like itever before. Just how (or why) so few want to neglect or dismiss the fact that simply no other drug has ever, to any degree, however minor, ever demonstrated even a fraction of the favorable outcomes A2-73 did in Alzheimer's sufferers is beyond me.

The statistical validity of the findings are unassailable. You can't get a year-long placebo effect in every 25 Alzheimer's participant.